Results 71 to 80 of about 52,949 (209)

Abstract 621: High-dose gefitinib overcomes the resistance to gefitinib related to hepatocyte growth factor

, 2010
Molecular targeted agents are being a mainstay in non-small cell lung cancer. Dramatic responses to the epidermal growth factor receptor (EGFR) -tyrosine kinase inhibitor (TKI) are observed in advanced non-small cell lung cancer (NSCLC), especially with ...
Eiki Ichihara, Mitsune Tanimoto, Hiromi Kashihara, Nagio Takigawa, Toshio Kubo, Saburo Takata, Kadoaki Ohashi, Katsuyuki Kiura, Kunio Matsumoto, Hiromasa Takeda, Masanori Fujii   +10 more
core   +1 more source

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

British Journal of Pharmacology, EarlyView.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown, Alan Armstrong, David J. Mann   +2 more
wiley   +1 more source

Clinical and Imaging Features of Tepotinib‐Induced Interstitial Lung Disease in the Post‐Marketing Setting in Japan

Cancer Science, EarlyView.
This article reports on the clinical and imaging features of tepotinib‐induced interstitial lung disease (ILD), which were evaluated by an ILD adjudication committee composed of external respiratory and radiology experts, and the committee expertly identified 35 patients with tepotinib‐induced ILD from spontaneous adverse event reports accumulated in ...
Terufumi Kato, Tomohisa Baba, Masahiro Endo, Shehla Endo, Eisuke Horii, Masahiko Kusumoto   +5 more
wiley   +1 more source

Gefitinib-Related Interstitial Lung Disease in Taiwanese Patients With Non-Small-Cell Lung Cancer

, 2014
Gefitinib is effective in the treatment of non-small-cell lung cancer (NSCLC), especially in the Asian population. However, interstitial lung disease (ILD) is usually a serious pulmonary adverse effect.
Chang, Shih-Chieh;Chang, Cheng-Yu;Chang, Shu-Ju;Yuan, Mei-Kang;Lai, Yi-Chun;Liu, Yu-Chang;Chen, Cheng-Yu;Kuo, Li-Chiao;Yu, Chong-Jen, 余忠仁   +1 more
core  

Effect of Gefitinib on EMT.

, 2013
(A) HCC827 GR5 cells were deprived of gefitinib for 1, 7, 14, 21 or 30 days. Expression of the indicated proteins was analyzed by Western blotting at each time point. Results are representative of three independent experiments.
Marcello Tiseo (475209), Maricla Galetti (475203), Claudia Fumarola (475204), Elisa Giovannetti (121153), Roberta R. Alfieri (475212), Mara Bonelli (475205), Pier Giorgio Petronini (475211), Andrea Cavazzoni (475206), Cristina Caffarra (475200), Rita Sirangelo (475208), Andrea Ardizzoni (475210), Silvia La Monica (475199), Elena Galvani (475202), Francesca Saccani (475201), Daniele Cretella (475207), Rita Gatti (206760)   +15 more
core   +1 more source

Lung Cancer Brain Metastasis: Brain Microenvironmental Adaptation, Therapeutic Resistance and Translational Strategies

Cancer Science, EarlyView.
Lung cancer brain metastasis is shaped by dynamic crosstalk among tumor cells, the blood–brain barrier, glial and immune cells, neurons, and metabolic niches. This review integrates these mechanisms with therapeutic resistance, translational models, CNS delivery, and multidisciplinary treatment strategies.
Jun Yang, Junyi Xiong, Li Ying, Yanyang Zeng, Ziqiang Ouyang, Mei Liu, Meihua Li   +6 more
wiley   +1 more source

Deubiquitination of epidermal growth factor receptor by ubiquitin-specific peptidase 54 enhances drug sensitivity to gefitinib in gefitinib-resistant non-small cell lung cancer cells.

PLoS ONE
A precise balance between ubiquitination and deubiquitination is crucial for cellular regulation. Ubiquitin-specific peptidase 54 (USP54), an active deubiquitinase (DUB), modulates the ubiquitination of the epidermal growth factor receptor (EGFR).
Mi Seong Kim, Min Seuk Kim
doaj   +1 more source

Comprehensive Genomic Profiling Beyond Driver Testing in Non‐Squamous Non‐Small Cell Lung Cancer With Known Drivers

Cancer Science, EarlyView.
Figure 6 Comprehensive genomic profiling identified additional actionable alterations in a substantial proportion of patients with non‐squamous NSCLC despite previously identified driver alterations, with some findings leading to subsequent matched targeted therapies.
Yoshihiro Masui, Tatsuya Yoshida, Yoh Yamaguchi, Jun Miyakoshi, Ryoko Inaba Higashiyama, Akiko Tateishi, Yuki Shinno, Yuji Matsumoto, Yusuke Okuma, Tomonori Mizutani, Hidehito Horinouchi, Kouya Shiraishi, Takashi Kohno, Takafumi Koyama, Noboru Yamamoto, Yasushi Goto   +15 more
wiley   +1 more source

Gefitinib induces autophagic flux.

, 2013
(A - D) Autophagic flux assays performed in SKBR3 cells. (A) Western blot analysis of p62 expression in lysates derived from cells treated for 3 h with vehicle (0 µM gefitinib) or increasing concentrations of gefitinib (Gef) (B) Western blot analysis of ...
Ling Yan Wong (470044), Anita I. Kapanen (470045), Wieslawa H. Dragowska (470042), Jenna S. Rawji (470046), Mohammed A. Qadir (470047), Marcel B. Bally (390199), Sharon M. Gorski (267185), Michel Roberge (155980), Corinna Warburton (390196), Jun Chih Wang (470043), Karen A. Gelmon (470048), Elizabeth Donohue (215530), Sherry A. Weppler (390194)   +12 more
core   +1 more source

Comparative Phenotypic and Molecular Characterisation of Feline Oral Squamous Cell Carcinoma Cell Lines Reveals Marked Biological Heterogeneity

Veterinary and Comparative Oncology, EarlyView.
ABSTRACT Feline oral squamous cell carcinoma (FOSCC) is the most common oral malignancy, characterised by aggressive local invasion, frequent bone involvement, and poor prognosis. The limited availability of well‐characterised in vitro models has hindered the understanding of tumour heterogeneity and invasive behaviour.
Qaisar Tanveer, Lisa Y. Pang, Colin Farquharson, Gurå Therese Bergkvist   +3 more
wiley   +1 more source